2O1O

Cryptosporidium parvum putative polyprenyl pyrophosphate synthase (cgd4_2550) in complex with risedronate.


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.42 Å
  • R-Value Free: 0.213 
  • R-Value Work: 0.186 

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis

Artz, J.D.Dunford, J.E.Arrowood, M.J.Dong, A.Chruszcz, M.Kavanagh, K.L.Minor, W.Russell, R.G.Ebetino, F.H.Oppermann, U.Hui, R.

(2008) Chem Biol 15: 1296-1306

  • DOI: 10.1016/j.chembiol.2008.10.017
  • Primary Citation of Related Structures:  
    2Q58, 2O1O

  • PubMed Abstract: 
  • Cryptosporidiosis is a neglected disease without a wholly effective drug. We present a study demonstrating nitrogen-containing bisphosphonates (N-BPs) to be capable of inhibiting Cryptosporidium parvum at low micromolar concentrations in infected MDCK cells ...

    Cryptosporidiosis is a neglected disease without a wholly effective drug. We present a study demonstrating nitrogen-containing bisphosphonates (N-BPs) to be capable of inhibiting Cryptosporidium parvum at low micromolar concentrations in infected MDCK cells. Predictably, the mechanism of action is based on inhibition of biosynthesis of isoprenoids but the target enzyme is unexpectedly a distinctive C. parvum enzyme dubbed nonspecific polyprenyl pyrophosphate synthase (CpNPPPS). This enzyme produces various isoprenoid products larger than FPP and is inhibited by N-BPs at subnanomolar concentrations. It is part of an isoprenoid pathway in Cryptosporidium distinctly different from other organisms. The proposed mechanism of action is corroborated by crystal structures of the enzyme with risedronate and zoledronate bound showing how this enzyme's unique chain length determinant region enables it to accommodate larger substrates and products. These results, combined with existing data on their clinical use, demonstrate that N-BPs are very promising anticryptosporidial drug candidates.


    Organizational Affiliation

    Structural Genomics Consortium, University of Toronto, 101 College Street, Toronto, ON M5G 1L7, Canada.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Putative farnesyl pyrophosphate synthaseA, B368Cryptosporidium parvumMutation(s): 0 
Gene Names: cgd4_2550
Find proteins for Q5CR09 (Cryptosporidium parvum (strain Iowa II))
Explore Q5CR09 
Go to UniProtKB:  Q5CR09
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
RISKi:  0.3799999952316284   nM  Binding MOAD
RISKi:  0.3799999952316284   nM  BindingDB
RISIC50:  45.70000076293945   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.42 Å
  • R-Value Free: 0.213 
  • R-Value Work: 0.186 
  • Space Group: P 31
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 101.758α = 90
b = 101.758β = 90
c = 75.313γ = 120
Software Package:
Software NamePurpose
SHELXL-97refinement
HKL-3000data reduction
HKL-3000data scaling
MOLREPphasing
RESOLVEphasing

Structure Validation

View Full Validation Report



Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2006-12-12
    Type: Initial release
  • Version 1.1: 2008-05-01
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2018-01-24
    Changes: Refinement description, Structure summary